Yahoo Web Search

Search results

1. en.wikipedia.org › wiki › Ingmar_HoerrIngmar Hoerr - Wikipedia

   en.wikipedia.org › wiki › Ingmar_Hoerr

   • Cached

   Ingmar Malte Hoerr (born 1968 in Neckarsulm) is a German biologist. He pioneered vaccinology research concerning the use of RNA and is a founder of the German biotechnology company CureVac. He created the initial technology used in RNA vaccines and has reportedly been nominated for a Nobel Prize. [1]

2. www.nature.com › articles › s41587/022/01234-0First Rounders: Ingmar Hoerr | Nature Biotechnology

   www.nature.com › articles › s41587/022/01234-0

   Feb 15, 2022 · Ingmar Hoerr is a co-founder and former CEO of CureVac. His conversation with Nature Biotechnology covers his initial discovery with RNA while in his PhD program, the struggle to find venture...

3. Images

   • 
   • 
   • 
   • 

   View all

4. www.chemistryviews.org › details › ezineInterview with Ingmar Hoerr, Pioneer of mRNA Technology

   www.chemistryviews.org › details › ezine

   • Cached

   May 4, 2021 · Here, Ingmar Hoerr talks with Vera Koester for ChemistryViews about his research, mRNA COVID-19 vaccines, and inspiring entrepreneurs and pioneers. What sparked your interest in mRNA research and what motivated you to do your Ph.D. with an immunologist and an organic chemist as supervisors?

5. www.nature.com › articles › d41586/021/02483-wThe tangled history of mRNA vaccines - Nature

   www.nature.com › articles › d41586/021/02483-w

   • Cached

   Sep 14, 2021 · Ingmar Hoerr (left) founded CureVac, and cancer immunologist Eli Gilboa (right) founded the first mRNA therapeutics firm. Credit: Sebastian Gollnow/dpa/Alamy; Eli Gilboa

   • Author: Elie Dolgin

   • Publish Year: 2021

6. Videos

   • 

     18:04

     youtube.com

     Ingmar Hoerr über die Entdeckung einer neuen Impfmethode | Markus Lanz vom 26. November 2020

     Nov 27, 2020

     149.5K Views

   • 

     10:13

     facebook.com

     Impfstoff-Pionier und CureVac-Gründer: Die Geschichte von Ingmar Hoerr | stern TV

     Jun 24, 2021

     24.4K Views

   • 

     19:06

     youtube.com

     RNA Pioneer, Ingmar Hoerr — The Blueprint of Life #TOA23

     Sep 27, 2023

     29 Views

   View all

7. de.wikipedia.org › wiki › Ingmar_HoerrIngmar Hoerr – Wikipedia

   de.wikipedia.org › wiki › Ingmar_Hoerr

   • Cached

   Ingmar Malte Hoerr (auch Hörr, * 3. Juni 1968 in Neckarsulm) [1] ist ein deutscher Biologe. Hoerr ist einer der Gründer von CureVac und war langjähriger Vorstandsvorsitzender des Unternehmens. Inhaltsverzeichnis. 1 Werdegang. 2 CureVac. 3 Ehrungen. 4 Patente. 5 Publikationen. 6 Literatur. 7 Weblinks. 8 Einzelnachweise. Werdegang.

8. www.europabio.org › interview-with-ingmar-hoerrInterview with Ingmar Hoerr, CureVac Founder and holder of ...

   www.europabio.org › interview-with-ingmar-hoerr

   • Cached

   Dec 13, 2021 · About Ingmar Hoerr. Ingmar Hoerr is a German biologist. He pioneered vaccinology research into the use of mRNA and is a founder of the German biotechnology company CureVac. He created the initial technology used in mRNA vaccines and submitted some of the first patents linked to its use, underpinning the role we see for it in current vaccine ...

9. People also ask

   Who is Ingmar Malte Hoerr?

   • Ingmar Malte Hoerr (born 1968 in Neckarsulm) is a German biologist. He pioneered vaccinology research concerning the use of RNA and is a founder of the German biotechnology company CureVac. He created the initial technology used in RNA vaccines and has reportedly been nominated for a Nobel Prize.

   Ingmar Hoerr - Wikipedia

   en.wikipedia.org/wiki/Ingmar_Hoerr

   See all results for this question

   How many patents does Ingmar Hoerr have?

   • Ingmar Hoerr holds over 30 patents. CureVac’s, BioNTech’s, and Moderna’s COVID-19 vaccines contain an mRNA that is taken up by cells after injection into a muscle and used to form the spike protein of SARS-CoV-2. The protein, which is foreign to the body, then stimulates the formation of antibodies.

   Interview with Ingmar Hoerr, Pioneer of mRNA Technology

   www.chemistryviews.org/details/ezine/11297010/Interview_with_Ingmar_Hoerr_Pioneer_of_mRNA_Technology/

   See all results for this question

   Why did Ingmar Hoerr create CureVac?

   • In 2000, Ingmar Hoerr and colleagues founded CureVac, a biopharmaceutical company that develops therapies based on mRNA, in Tübingen, Germany. The basis for that was his discovery during his Ph.D. thesis that naked mRNA can be expressed in vivo without being rapidly degraded and that it generates a strong specific immune response.

   Interview with Ingmar Hoerr, Pioneer of mRNA Technology

   www.chemistryviews.org/details/ezine/11297010/Interview_with_Ingmar_Hoerr_Pioneer_of_mRNA_Technology/

   See all results for this question

   How did Eli Gilboa and Ingmar Hoerr develop mRNA?

   • Both Ingmar Hoerr, at CureVac, and Uğur Şahin, at BioNTech, told Nature that, after learning of what Gilboa had done, they wanted to do the same, but by administering mRNA into the body directly. Ingmar Hoerr (left) founded CureVac, and cancer immunologist Eli Gilboa (right) founded the first mRNA therapeutics firm.

   The tangled history of mRNA vaccines - Nature

   www.nature.com/articles/d41586-021-02483-w

   See all results for this question

10. www.insights.bio › vaccine-insights › journalRNA pioneer Ingmar Hoerr: from entrepreneur to philanthropist

    www.insights.bio › vaccine-insights › journal

    Aug 24, 2022 · RNA pioneer Ingmar Hoerr: from entrepreneur to philanthropist. Vaccine Insights 2022; 1 (4), 201–205. DOI: 10.18609/vac.2022.30. Published: 24 August 2022. Interview. Ingmar Hoerr. Charlotte Barker, Editor, BioInsights, speaks to Ingmar Hoerr, co-founder of CureVac & Morpho Foundation.